National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation

Journal of Medical Virology

Volumn 80, Issue 5, 2008, Pages 762-765

  Delaugerre, C ^a,l,m   Flandre, P ^b   Marcelin, A G ^c   Descamps, D ^d,m   Tamalet, C ^e,m   Cottalorda, J ^f,m   Schneider, V ^g,m   Yerly, S ^h,m   LeGoff, J ⁱ   Morand Joubert, L ^j,m   Chaix, M L ^k,m   Costagliola, D ^b   Calvez, V ^c,m   Masquelier, B ^m   Brun Vezinet F ^m   Izopet, J ^m   Marcellin, A G ^m   Ruffault, A ^m   Peytavin, G ^m   Bouvier, M ^m   Roussel, C ^m   Vabret, A ^m   Kholi, E ^m   more..

^a Hôpital Universitaire Ambroise Paré   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d BICHAT HOSPITAL   (France)

^e TIMONE HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NICE   (France)

^g HÔPITAL TENON   (France)

^h Hôpital Universitaire HUG   (Switzerland)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j HÔPITAL SAINT ANTOINE   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m HEGP ^*

more..

Author keywords

Drug resistance; HIV; K70E mutation; Tenofovir; Thymidine analogs mutations

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SELECTION; GENOTYPE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RETROSPECTIVE STUDY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 41849113448     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21158     Document Type: Article

References (19)

1. Bradshaw D, Malik S, Booth C, Van Houtte M, Pattery T, Waters A, Ainsworth J, Geretti AM. 2007. Characterization of a novel drug-resistance pattern associated with the mutations K70G and M184V in HIV-1 reverse transcriptase. Antimicrob Agents Chemother 51:4489-4491.
2. Delaugerre C, Roudiere L, Peytavin G, Rouzioux C, Viard JP, Chaix ML. 2005. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol 32:241-244.
3. Descamps D, Delaugerre C, Masquelier B, Ruffault A, Marcelin AG, Izopet J, Chaix ML, Calvez V, Brun-Vezinet F, Costagliola D. 2006. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 78:153-160.
4. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 292:191-201.
5. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK. 2006. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354:251-260.
6. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. 2007. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 15:119-125.
7. Kagan R, Ross L, Winters T, Merigan P, Heseltine P, Lewinski M. 2005. Adefovir-associated HIV-1 RT mutation K70E in the age of tenofovir. Antivir Ther 9:827-828.
8. Lloyd R, Huong j, Rouse E, Gerondelis P, Lim M, Shaefer M, Rodriguez A, Gallant J, Lanier R, Ross L. 2005. HIV-1 RT mutations K70E and K65R are not present on the same viral genome when both mutations are detected in plasma, abstr. 1066; Washington, USA.
9. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. 2002. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS (London, England) 16:1227-1235.
10. Margot NA, Lu B, Cheng A, Miller MD. 2006. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 7:442-450.
11. Miller MD, Lamy PD, Fuller MD, Mulato AS, Margot NA, Cihlar T, Cherrington JM. 1998. Human immunodeficiency virus type 1 reverse transcriptase expressing the K70E mutation exhibits a decrease in specific activity and processivity. Mol Pharmacol 54:291-297.
12. Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. 1999. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J Infect Dis 179:92-100.
13. Mulato AS, Lamy PD, Miller MD, Li WX, Anton KE, Hellmann NS, Cherrington JM. 1998. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy. Antimicrob Agents Chemother 42:1620-1628.
14. Roge BT, Katzenstein TL, Obel N, Nielsen H, Kirk O, Pedersen C, Mathiesen L, Lundgren J, Gerstoft J. 2003. K65R with and without S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther 8:173-182.
15. Ross L, Gerondelis P, Liao Q, Wine B, Lim M, Shaefer M, Rodriguez A, Limoli K, Huang W, Parkin NT, Gallant J, Lanier R. 2005. Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naive subjects treated with tenofovir/abacavir/lamivudine therapy. Antivir Ther 10:302.
16. Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW. 2007. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 51:48-53.
17. Van Houtte M, Staes M, Geretti AM, Pattery T, Bacheler L. 2006. NTI resistance associated with the RT mutation K70E in HIV-1. Antivir Ther 11:S160.
18. Van Rompay KKA, Johnson JA, Blackwood EJ, Lipscomb J, Bischofberger N, Heneine W, North TW. 2006. Sequential emergence and clinical implications of K70E and K65R viral mutants during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Antivir Ther 11:S41.
19. Zelina S, Sheen CW, Mellors JW, Sluis-Cremer N. 2006. Residue K70 in HIV-1 reverse transcriptase: A crossroad between excision and discrimination mechanisms of NRTI resistance. Antivir Ther 11:S159.